Kyverna Therapeutics (KYTX) Total Liabilities (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Total Liabilities came in at $61.4 million in Q1 2026, up 67.67% YoY from $36.6 million in Q1 2025, and little changed on a QoQ basis from $61.6 million in Q4 2025.
Kyverna Therapeutics (KYTX) Total Liabilities (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Total Liabilities data on file, last reported at $61.4 million in Q1 2026.
- Quarterly Total Liabilities rose 67.67% year-over-year to $61.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.4 million (up 67.67% YoY) and the FY2025 annual result came in at $61.6 million, up 61.73% from the prior year.
- Total Liabilities steadied at $61.4 million in Q1 2026, from $61.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $61.6 million in Q4 2025 to a low of $26.0 million in Q4 2023.
- A 4-year average of $39.6 million and a median of $36.6 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2025 — Total Liabilities retreated 3.5% — and 2026, when it surged 67.67%.
- Tracing KYTX's Total Liabilities over 4 years: stood at $26.0 million in 2023, then surged by 46.28% to $38.1 million in 2024, then surged by 61.73% to $61.6 million in 2025, then decreased by 0.17% to $61.4 million in 2026.
- The last three Total Liabilities figures came in at $61.4 million (Q1 2026), $61.6 million (Q4 2025), and $35.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 54.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.27 Mn |
| Mar 31, 2026 | 61.44 Mn |
| Dec 31, 2025 | 61.55 Mn |
| Sep 30, 2025 | 35.21 Mn |
| Jun 30, 2025 | 42.13 Mn |
| Mar 31, 2025 | 36.65 Mn |
| Dec 31, 2024 | 38.06 Mn |
| Sep 30, 2024 | 36.49 Mn |
| Jun 30, 2024 | 29.61 Mn |
| Mar 31, 2024 | 28.99 Mn |
| Dec 31, 2023 | 26.02 Mn |